Answers are grounded in this paper and cite their sources.
Congenital afibrinogenaemia, OMIM No. 202400, is a rare coagulation disorder that features very low or undetectable plasma levels of functional and immunoreactive fibrinogen [1], which is essential for the formation of fibrin clots. The frequency of this disorder is higher among communities in which consanguineous marriages are prevalent [2], and affected individuals show diverse haemorrhagic manifestations throughout their life. Umbilical cord haemorrhage is often the first sign of the genetic disorder while gum bleeding, epistaxis, menorrhage, muscle haematomas and haemarthrosis may appear repeatedly and with varying degrees of intensity over the years; moreover, spontaneous intracerebral bleeding or splenic rupture may also occur [3, 4]. Furthermore, afibrinogenaemic women show recurrent abortions and, in general, other thrombotic events caused by the lack of fibrin on to which thrombin can be adsorbed [4, 5]. Fibrinogen is comprised by 2 sets of 3 homologous polypeptide chains: Aα, Bβ and γ. Each polypeptide chain is encoded by a different gene, FGA, FGB or FGG, respectively, and all 3 are clustered in a region of 50 kb on 4q31.3. To date, some 72 causative mutations of this group have been reported [6] and the most frequent one affects the donor splice site of intron 4 in the fibrinogen α gene, leading to a downstream cryptic splice site utilization [7]. In this work, we describe a congenital afibrinogneaemia in a Venezuelan 5-year-old girl. The coding region and the intron/exon boundaries of all 3 fibrinogen genes were amplified and the resulting PCR products were directly sequenced on an automatic DNA sequencer (Genetic Analyzer ABI 310, Applied Biosystems, Foster City, Calif., USA), using BigDye®Cycle Sequencing Kits (Applied Biosystems). The DNA analyses revealed that the proband girl was homozygous for a nonsense mutation in the FGA gene at g.3807C→T. The mutation is predicted to cause an early truncation at Aα 159 Arg (numbering starts at residue 1 of the predicted mature polypeptide). Interestingly, both parents of the girl showed the same mutation, although in the heterozygous form.Clotting tests of plasma samples from the girl revealed an infinite thrombin time (>120 s, control adjusted to 19–21 s; Laboratoire Stago, Asnière, France) and the lack of both functional (Clauss fibrinogen test <10 mg/dl, normal range 150–450; STA Compact®, Stago, France) and gravimetric fibrinogen (<10 mg/dl). The predominant symptom caused by these deficiencies was posttraumatic haematomas that required blood transfusions in several instances. In contrast, even though her parents are heterozygous for an essentially null mutation, their circulating fibrinogen concentrations remained normal (260 and 290 mg/dl in the mother and father, respectively, measured by means of the gravimetric method). We tested the plasma from the girl for polymerization using bovine thrombin (Sigma, St. Louis, Mo., USA) at a final concentration of 12 units/ml (i.e. 20 times more than normally used) but the results were negligible, whereas the samples from her parents showed normal polymerization kinetics. Also, the absence of fibrinogen molecules containing the mutated Aα chain in the parents was confirmed by immunoblotting, which also verified that no fibrinogen could be detected in the proposita (fig. 1).It has been stated that carriers of afibrinogenaemia mutations, usually hypofibrinogenaemic parents, have normal levels of this protein at about 100 mg/dl [6]. However, a recent report on 2 novel hypofibrinogenaemia cases indicates that individuals with the same kind of mutation may show significantly different blood fibrinogen levels, ranging from 63 to 163 mg/dl [9]. The authors of that study reason that the difference may be related to the polymorphism –128 C→G in the FGA promoter region. In our case, it would be of interest to study polymorphic variants in relation to increased fibrinogen levels. This could help to clarify why the proband’s parents carry a nonsense mutation yet they show normal circulating fibrinogen values. Until now, only another single case has been reported carrying the same mutation as that described here. It was termed ‘fibrinogen Greelong’ [10], but it is a compound heterozygote for another mutation in the fibrinogen Aα gene, a single deletion of the 1215t nucleotide. In both cases, the afibrinogenaemic phenotype may be ascribed to the early truncation of the Aα chain prior to the completion of the second disulphide ring of the coiled coil that starts at Aα 161 Cys; that ring is a critical requisite for the formation of a stable 3-chained half molecule [11]. We were unable to compare the parents of fibrinogen Greelong with our subjects, as the former proband was adopted and no further information is available concerning his biological parents. Nonetheless, while our study appears to be the second report of afibrinogenaemia involving the g.3807C→T nonsense mutation in FGA, this is the first time that it has been examined in the homozygous state.We want to thank MSc. Zoila Carvajal for the technical assistance.
No takes yet. Share an insight, caveat, or question.
Cappelletti et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: